The deal has been approved by the boards of both companies. However, Harris Teeter has yet to receive shareholder approval.
Kroger will finance the deal with debt, and will therefore allocate some free cash flow to reduce its current debt burden in the subsequent quarters. Kroger expects net accretion to earnings per share in the range of 6 ��9 cents in year-one after the merger.
After the completion of the deal, Harris Teeter will become a subsidiary of Kroger. It will retain Harris Teeter�� senior management and its headquarters at Matthews, NC. Kroger will not sell any of the Harris Teeter stores until there is an overlap in any of the Harris Teeter�� markets.
Top 5 Canadian Companies To Watch In Right Now: Westar Energy Inc.(WR)
Westar Energy, Inc., an electric utility company, engages in the generation, transmission, and distribution of electricity. It produces electricity through various sources, including coal, wind, nuclear, natural gas, oil, and diesel. As of October 26, 2011, it served approximately 687,000 residential, commercial, and industrial customers in Kansas; and had approximately 7,100 megawatts of generating capacity, as well as operated and coordinated approximately 34,000 miles of electric distribution and transmission lines. Westar Energy, Inc. also engages in energy marketing, and in the purchase and sale of electricity. It serves public streets, highways, electric cooperatives, municipalities, and other electric utilities in central and northeastern Kansas, including the cities of Topeka, Lawrence, Manhattan, Salina, and Hutchinson. The company was founded in 1924 and is headquartered in Topeka, Kansas.
Advisors' Opinion:- [By Ben Levisohn]
Now don’t misunderstand. Gordon isn’t telling investors to avoid all regulated utilities. He has some favorites, including American Electric Power (AEP), Dominion Resources (D), ITC Holdings (ITC), Pinnacle West Capital (PNW) and Westar Energy (WR).
Top 10 Supermarket Companies To Invest In 2014: Array BioPharma Inc.(ARRY)
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. Its programs under development include ARRY-520, a kinesin spindle protein inhibitor in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie-2 dual inhibitor in Phase 1 clinical trial for patients with myelodysplastic syndrome; ARRY-380, a HER2 inhibitor in Phase 1 clinical trial for breast cancer; ARRY-797, a p38 inhibitor in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist in Phase 1 clinical trial for allergic inflammation. The company?s partnered drugs in clinical development comprise Selumetinib and AZD8330 MEK inhibitors for cancer in Phase 2 trial; MEK162 and MEK300 MEK inhibitors for cancer in Phase 2 trial; Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 trial; ARRY-543, a HER2/EGFR inhibitor in Phase 2 trial for solid tumors; and LY2603618, a ChK-1 inhibitor in Phase 2 trial for cancer. Its partnered drugs in clinical development also include AMG 151, a glucokinase activator in Phase 1b trial for Type 2 diabetes; GDC-0068, a AKT inhibitor in Phase 1b trial for cancer; VTX-2337, a toll-like receptor in Phase 1b trial for cancer; VTX-1463, a toll-like receptor in Phase 1b trial for allergy; ARRY-382, a cFMS inhibitor in Phase 1 trial for cancer; and ARRY-575 and GDC-0425, which are ChK-1 inhibitors in Phase 1 trial for cancer. The company has collaborations with Amgen, Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Genentech, Inc.; Novartis International Pharmaceutical Ltd.; InterMune, Inc.; Eli Lilly and Company; and VentiRx Pharmaceuticals, Inc for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Advisors' Opinion:- [By Dan Carroll]
Array's phase 2 study pays off big
It's tough to find a stock anywhere on the market that had as good a week as Array BioPharma (NASDAQ: ARRY ) . Shares of the biotech picked up nearly 17.8% on the week, part of a 63.5% gain year-to-date. The company's developmental drug to treat persistent allergic asthma, ARRY-502, hit the right marks in improving patient lung function in phase 2 trial results. Even better for investors, Array CEO said several other health companies have shown interest to help the company in development of ARRY-502. - [By Sean Williams]
Shareholders "nudged" Array BioPharma (NASDAQ: ARRY ) higher by nearly 18% on the week after it announced positive mid-stage data on ARRY-502, a treatment for mild to moderate persistent allergic asthma. In its mid-stage trial, ARRY-502 met its primary endpoint of improving lung function as measured by forced expiratory volume in one second, or FEV1. In the overall trial, FEV1 increased by 3.9% compared to the placebo, while a specified subset of patients in the Th2 Biomarker group saw their FEV1 jump by 6.8% relative to the placebo. ARRY-502 also met a number of secondary endpoints. Since the asthma market is a crowded field, Array also put the feelers out there that it's looking for a licensing partner to help take this experimental drug into the next stage.
- [By Sean Williams]
Array BioPharma (NASDAQ: ARRY ) presented some particularly intriguing findings with its MEK inhibitor, selumetinib, which it has licensed out to AstraZeneca�to treat uveal melanoma (cancer of the eye). Historically this is a very difficult to treat disease, but initial studies of selumetinib more than doubled the time it took for the disease to progress compared to the current standard of treatment, temozolomide. In trials, selumetinib delivered 15.9 weeks without disease progression, an overall response rate of 50%, and major tumor shrinkage exhibited in 15% of patients. For temozolomide, steady disease was only established for a median of seven weeks with no tumor shrinkage present.�
Top 10 Supermarket Companies To Invest In 2014: Cell Therapeutics Inc (CTIC)
Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.
Pixuvri
As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.
OPAXIO
OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.
Tosedostat
In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.
Brostallicin
As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).
The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.
Advisors' Opinion:- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:
Top 10 Supermarket Companies To Invest In 2014: Mindspeed Technologies Inc.(MSPD)
Mindspeed Technologies, Inc. designs, develops, and sells semiconductor networking solutions for communications applications in enterprise, fixed and mobile broadband access, metropolitan, and wide-area networks (WAN). The company offers communications convergence processing products that serve as bridges for transporting video, voice, fax, and modem transmissions between circuit-switched and packet-based fixed and mobile networks, and across network boundaries; and offer video and voice over Internet protocol, voice-over-asynchronous transfer mode (ATM), and voice-over-digital subscriber line services, as well as wireline-to-wireless connectivity. These products include the eighth-generation Comcerto family for fiber-access service delivery; and Transcede family of 3G/4G base station baseband processors. It also provides analog transmission devices and switching products, which comprise laser drivers, transimpedance amplifiers, post amplifiers, clock and data recovery cir cuits, signal conditioners, serializers/deserializers, video reclockers, cable drivers, and line equalizers that support storage area network, fiber-to-the-premise, optical transport networks, and broadcast video. In addition, the company offers WAN communications products comprising transmission solutions and ATM/multi-protocol label switching network processors that facilitate the aggregation, processing, and transport of voice and data traffic over copper wire or fiber optic cable to access metropolitan and long-haul networks. It sells its products directly to network infrastructure original equipment manufacturers; and indirectly through electronic component distributors and third-party electronic manufacturing service providers in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. The company was founded in 2001 and is headquartered in Newport Beach, California.
Advisors' Opinion:- [By Lauren Pollock]
M/A-COM Technology Solutions Holdings Inc.(MTSI) agreed to acquire semiconductor manufacturer Mindspeed Technologies Inc.(MSPD) in a deal valued at $272 million, expanding the company’s markets to include enterprise applications. Mindspeed shares surged 70% to $5.04 premarket.
- [By Lee Jackson]
Mindspeed Technologies Inc. (NASDAQ: MSPD) provides voice over internet protocol (VOIP) infrastructure and some telecom chips, which account for about 10% of sales. This could disrupt earnings at a micro cap tech company. The consensus price target for the stock is $3.75.
Top 10 Supermarket Companies To Invest In 2014: ICSGlobal Ltd (ICS)
ICSGlobal Limited is an Australia-based company. The principal activities of the Company during the fiscal year ended June 30, 2012 (fiscal 2012), were the operations of a holding company in Australia with a 100% owned subsidiary providing medical billing services in the United Kingdom. As of June 30, 2012, the Company owned Medical Billing and Collections (MBC) in the United Kingdom. The Company has owned a number of operating companies in Australia, the United States and the United Kingdom. As of June 30, 2012, the Company is focused on new business opportunities. As of June 30, 2012, the Company�� subsidiaries included Thelma Pty Ltd, EziBill Pty Ltd and Thelma-EU Limited. Advisors' Opinion:- [By Dividends4Life]
This week a few companies answered the call and rewarded their shareholders with higher cash dividends:
Consolidated Edison Inc. (ED) engages in regulated electric, gas, and steam delivery businesses. January 16th the company increased its quarterly dividend 2.4% to $0.63 per share. The dividend is payable March 15, 2014, to stockholders of record on February 12, 2014. The yield based on the new payout is 4.7%.
Cousins Properties Incorporated (CUZ), a real estate investment trust (REIT), owns, develops, and manages real estate portfolio, as well as performs certain real estate-related services. January 16th the company increased its quarterly dividend 66.7% to $0.075 per share. The dividend is payable February 24, 2014, to stockholders of record on February 10, 2014. The yield based on the new payout is 2.8%.
Wisconsin Energy Corporation (WEC) generates and distributes electric energy, as well as distributes natural gas. The company operates in two segments, Utility Energy and Non-Utility Energy. January 16th the company increased its quarterly dividend 2% to $0.3900 per share. The dividend is payable March 1, 2014, to stockholders of record on February 14, 2014. The yield based on the new payout is 3.8%.
BlackRock Inc. (BLK) is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors. January 16th the company increased its quarterly dividend 14.9% to $1.93 per share. The dividend is payable March 24, 2014, to stockholders of record on March 7, 2014. The yield based on the new payout is 2.4%.
ONEOK Inc. (OKE) operates as a diversified energy company in the United States. January 15th the company increased its quarterly dividend 5.3% to $0.40 per share. The dividend is payable February 18, 2014, to stockholders of record on February 10, 2014. The yield based on the new payout is 2.5%.
Omega Healthcare Investors Inc. (OHI) is a real es - [By ovenerio]
In this article, let's take a look at Analog Devices, Inc. (ADI), a $15.79 billion market cap company, which is a company that manufactures high-performance integrated circuits (ICs) used in analog and digital signal processing applications.
Top 10 Supermarket Companies To Invest In 2014: Hercules Technology Growth Capital Inc (HTGC)
Hercules Technology Growth Capital, Inc. (HTGC), incorporated on December 18, 2003, is an internally managed, non-diversified closed-end investment company. The Company is a specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and clean-technology industries at all stages of development. The Company's investment objective is to maximize the Company's portfolio total return by generating current income from its debt investments and capital appreciation from its equity-related investments. The Company invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The Company also makes investments in qualifying small businesses through two wholly-owned, small business investment company (SBIC) subsidiaries, Hercules Technology II, L.P. (HT II) and Hercules Technology III, L.P. (HT III).
The Company focuses its investments in companies active in the technology industry sub-sectors characterized by products or services that requires advanced technologies, including, but not limited to, computer software and hardware, networking systems, semiconductors, semiconductor capital equipment, information technology infrastructure or services, Internet consumer and business services, telecommunications, telecommunications equipment, renewable or alternative energy, media and life science. Within the life science sub-sector, the Company generally focuses on medical devices, bio-pharmaceutical, drug discovery, drug delivery, health care services and information systems companies. Within the clean technology sub-sector, the Company focuses on sustainable and renewable energy technologies and energy efficiency and monitoring technologies. The Company refers to all of these companies as technology-related companies and intend, under normal circumstances, to invest at least 80% of the value of its assets in such businesses. Advisors' Opinion:
- [By Helix Investment Research]
Keating Capital is far from the only publicly traded pre-IPO investment company. There are several others, including GSV Capital (GSVC) and Firsthand Technology Value Fund (SVVC). Hercules Technology Growth Capital (HTGC) is also a pre-IPO fund, but with the bulk of its assets (over 92%) invested into loans to and debt of private companies, as opposed to their equity, the company's investment philosophy is different than that of these other pre-IPO funds. Unlike GSV Capital and Firsthand, Keating Capital, as a matter of policy, always purchases equity directly from portfolio companies, never from secondary markets such as SharesPost or SecondMarket. Mr. Keating outlined that this is due to the company's requirement that it be given access to all relevant financial data and managerial projections of its portfolio companies at all times, something that Mr. Keating believes is essential to being able to make informed investor decisions. We note that shares of Facebook (FB) and Twitter are conspicuously absent from Keating Capital's portfolio; the company declined to purchase shares of either company due to an inability to acquire direct financial information regarding these companies. In addition, Keating Capital has a stated goal of investing in the most senior equity securities available at each portfolio company.
- [By Lawrence Meyers]
Business development companies like Hercules Technology Growth Capital (HTGC) invest money into middle-market companies that are experiencing fast growth.� Often, these investments take the form of mezzanine debt paying interest in the teens, and some warrants.� Hercules likes to focus more on senior secured revolvers and term loans to refinance existing debt, and will even take second-liens.� It has more attractive upside with its investments than other BDCs because it focuses on tech, energy tech, healthcare, life sciences and business services — all of which can fetch higher multiples upon exit.� It pays out a sturdy 7.3% dividend.
Top 10 Supermarket Companies To Invest In 2014: Rossi Residencial SA (RSID3)
Rossi Residencial SA is a Brazil-based company involved in the real estate sector. The Company is principally engaged in the development, construction and sale of residential and commercial real estate properties. In addition, it is involved in the subdivision of land and provision of civil engineering services. As of December 31, 2011, the Company had four subsidiaries, including Astir Assessoria Tecnica Imobiliaria e Participacoes Ltda, RCI Consultoria de Imoveis Ltda, Rossi Consultoria de Imoveis Ltda and Rossi Industria de Artefatos de Concreto Ltda, as well as a number of joint ventures, such as Argentea Empreendimentos SA, Damacena Empreendimentos SA, Minulo Empreendimentos SA and Nicandra Empreendimentos SA, among others. Advisors' Opinion:- [By Ney Hayashi]
MMX Mineracao & Metalicos SA rose to a one-week high after saying it is seeking partners to expand a mining project. Rossi Residencial SA (RSID3) led gains among homebuilders as traders reduced bets on higher borrowing costs. EDP-Energias do Brasil SA advanced after selling a stake in some of its power plants in Brazil to China Three Gorges Corp. Car-rental company Localiza Rent a Car SA climbed after Fitch Ratings increased its credit rating.
- [By Ney Hayashi]
Rossi Residencial SA (RSID3) climbed 2.1 percent today to 2.98 reais, leading homebuilders higher, as traders pared bets for higher borrowing costs in Brazil following the inflation report. The BM&FBovespa Real Estate Index added 0.5 percent.
By using RentalCars you can discover the best car hires from over 49,000 locations worldwide.
ReplyDelete